The estimated Net Worth of David A Scheinberg is at least $74.2 Thousand dollars as of 1 July 2019. David Scheinberg owns over 10,000 units of SELLAS Life Sciences Inc stock worth over $74,164 and over the last 22 years he sold SLS stock worth over $0. In addition, he makes $0 as Director at SELLAS Life Sciences Inc.
David has made over 17 trades of the SELLAS Life Sciences Inc stock since 2003, according to the Form 4 filled with the SEC. Most recently he exercised 10,000 units of SLS stock worth $53,300 on 1 July 2019.
The largest trade he's ever made was exercising 40,000 units of SELLAS Life Sciences Inc stock on 24 September 2003 worth over $213,200. On average, David trades about 2,857 units every 107 days since 2003. As of 1 July 2019 he still owns at least 56,185 units of SELLAS Life Sciences Inc stock.
You can see the complete history of David Scheinberg stock trades at the bottom of the page.
Dr. David A. Scheinberg M.D., Ph.D. serves as Director of the Company. Dr. Scheinberg has been a director of the Company since December 2017. Dr. Scheinberg is currently the Vincent Astor Chair and Chairman of Molecular Pharmacology, Sloan Kettering Institute. He also founded and chairs the Center for Experimental Therapeutics at MSK, where he spearheaded the discovery and early clinical development of galinpepimut-S and founded and was chair of the Nanotechnology Center from 2010 to 2014. Additionally, Dr. Scheinberg is a Professor of Medicine and Pharmacology and co-chair of the Pharmacology graduate program at the Weill-Cornell University Medical College and Professor in the Gerstner-Sloan Kettering Graduate School at MSK. Dr. Scheinberg is also an attending physician in the Department of Medicine, Leukemia Service and Hematology Laboratory Service/Department of Clinical Laboratories at Memorial Hospital. Dr. Scheinberg is an advisor to charitable foundations and cancer centers and sat on the board of directors of Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX), a biotechnology company, from 1996 to 2019, and currently sits on the board of directors of Sapience Therapeutics, Inc., a privately held, preclinical stage biotechnology company. Dr. Scheinberg also served on Private SELLAS’ Scientific Advisory Board from 2015 to 2017. From 2010 through 2016 he served on the board of directors of Contrafect Corporation, a publicly traded clinical-stage biotechnology company. Dr. Scheinberg holds an M.D. and a Ph.D. in Pharmacology and Experimental Therapeutics from the Johns Hopkins University School of Medicine. Dr. Scheinberg earned his undergraduate degree in Biology from Cornell University.
David Scheinberg is 64, he's been the Director of SELLAS Life Sciences Inc since 2017. There are no older and 15 younger executives at SELLAS Life Sciences Inc.
Over the last 7 years, insiders at SELLAS Life Sciences Inc have traded over $74,616 worth of SELLAS Life Sciences Inc stock. The most active insiders traders include John Varian, Jane Wasman, and David A Scheinberg. On average, SELLAS Life Sciences Inc executives and independent directors trade stock every 205 days with the average trade being worth of $6,842. The most recent stock trade was executed by Angelos M. Stergiou on 5 December 2022, trading 6,494 units of SLS stock currently worth $16,949.
σellas life sciences is a healthcare-oriented global group of companies with a unique and innovative vision, which is ambitious, yet clear: to practice the medicine of tomorrow, today. in other words, we incorporate innovation throughout all our activities aiming at breakthroughs that will have a significant impact on the thinking and practicing of healthcare worldwide. our international team of acknowledged scientists, doctors and health professionals along with a seasoned and highly experienced pharmaceutical executive management form the core of σellas. we strive to improve patients' quality of life through developing and commercializing cutting-edge drugs, medical devices and innovative therapies.
SELLAS Life Sciences Inc executives and other stock owners filed with the SEC include: